Androgen biosynthesis in castration-resistant prostate cancer

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Prostate cancer is a leading cause of male mortality in the USA.
• Castration-resistant prostate cancer (CRPC) persists despite low androgen levels.
• CRPC adapts through intratumoral androgen synthesis or androgen receptor (AR) alteration.

Purpose of the Study:

• Review androgen synthesis pathways in CRPC.
• Examine enzyme targets for inhibiting intratumoral androgen biosynthesis.
• Evaluate strategies to overcome drug resistance in CRPC treatment.

Main Methods:

• Literature review of CRPC androgenesis.
• Analysis of enzyme targets for androgen synthesis inhibition.
• Discussion of combination therapies and precision medicine approaches.

Main Results:

• CRPC cells synthesize androgens intratumorally.
• Enzyme inhibitors targeting androgen synthesis are under development.
• Pathway redundancy suggests potential for drug resistance.

Conclusions:

• Inhibiting single androgen synthesis pathways may lead to resistance.
• Multi-targeted drugs or bifunctional agents show promise for CRPC.
• Precision medicine is essential for tailoring CRPC treatments.